SG10201913643YA - N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors - Google Patents

N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Info

Publication number
SG10201913643YA
SG10201913643YA SG10201913643YA SG10201913643YA SG10201913643YA SG 10201913643Y A SG10201913643Y A SG 10201913643YA SG 10201913643Y A SG10201913643Y A SG 10201913643YA SG 10201913643Y A SG10201913643Y A SG 10201913643YA SG 10201913643Y A SG10201913643Y A SG 10201913643YA
Authority
SG
Singapore
Prior art keywords
benzamides
phenylsulfonyl
bcl
inhibitors
related compounds
Prior art date
Application number
SG10201913643YA
Inventor
Shaomeng Wang
Jianyong Chen
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of SG10201913643YA publication Critical patent/SG10201913643YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
SG10201913643YA 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors SG10201913643YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03

Publications (1)

Publication Number Publication Date
SG10201913643YA true SG10201913643YA (en) 2020-03-30

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913643YA SG10201913643YA (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201900135YA SG11201900135YA (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201900135YA SG11201900135YA (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Country Status (26)

Country Link
US (3) US10829488B2 (en)
EP (3) EP3569601B1 (en)
JP (2) JP6651180B2 (en)
KR (2) KR102429704B1 (en)
CN (2) CN109311871B (en)
AU (2) AU2017305508B2 (en)
BR (1) BR112019001666A2 (en)
CA (1) CA3031419C (en)
CY (1) CY1123859T1 (en)
DK (1) DK3494115T3 (en)
ES (1) ES2849959T3 (en)
HR (1) HRP20202073T1 (en)
HU (1) HUE053414T2 (en)
IL (2) IL264059B (en)
LT (1) LT3494115T (en)
MX (2) MX2019001391A (en)
PE (1) PE20190711A1 (en)
PH (1) PH12019500231A1 (en)
PT (1) PT3494115T (en)
RS (1) RS61821B1 (en)
RU (3) RU2744358C2 (en)
SA (1) SA519401020B1 (en)
SG (2) SG10201913643YA (en)
SI (1) SI3494115T1 (en)
WO (1) WO2018027097A1 (en)
ZA (2) ZA201900240B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426655A1 (en) * 2016-03-10 2019-01-16 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
EP3569601B1 (en) * 2016-08-05 2022-06-22 The Regents of The University of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
JP7085566B2 (en) * 2017-04-18 2022-06-16 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド Apoptosis inducer
BR112020022092A2 (en) 2018-04-29 2021-02-02 Beigene, Ltd. compounds, method for treating unregulated apoptotic diseases and pharmaceutical composition
CN110772521A (en) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2 inhibitor or Bcl-2/Bcl-xL inhibitor and BTK inhibitor combination product and application thereof
US11554127B2 (en) * 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CN110772639B (en) * 2018-07-31 2021-04-13 苏州亚盛药业有限公司 Combination of a Bcl-2inhibitor and an MDM 2inhibitor and its use in the prevention and/or treatment of diseases
TWI725488B (en) * 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Combination product of Bcl-2 inhibitor and chemotherapeutic agent and its use in preventing and/or treating disease
AU2019385458A1 (en) * 2018-11-23 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof
TWI770503B (en) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 Method and composition for predicting efficacy of bcl2/bcl-xl inhibitors
WO2021110097A1 (en) 2019-12-03 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
TW202114692A (en) * 2019-07-02 2021-04-16 大陸商蘇州亞盛藥業有限公司 A pharmaceutical combination containing mTOR inhibitor and use thereof
TW202114664A (en) * 2019-07-31 2021-04-16 大陸商蘇州亞盛藥業有限公司 Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
TW202134239A (en) * 2019-11-27 2021-09-16 大陸商蘇州亞盛藥業有限公司 Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
EP4069233A4 (en) * 2019-12-04 2024-03-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
US20230041515A1 (en) 2019-12-06 2023-02-09 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
EP3914596A4 (en) * 2020-03-06 2022-04-20 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates
US20230128137A1 (en) * 2020-03-12 2023-04-27 Medshine Discovery Inc. Benzo five-membered cyclic compound
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
CN113880834B (en) * 2020-07-01 2023-01-20 苏州亚盛药业有限公司 Synthesis method of N- (phenylsulfonyl) benzamide compound and intermediate thereof
CN111537654B (en) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 HPLC analysis method of N- (phenylsulfonyl) benzamide compound
BR112023000320A2 (en) * 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd SULFONYLBENZAMIDE DERIVATIVE AND ITS COJUGATE, METHOD OF PREPARATION AND ITS USE
CN114057728A (en) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 Heterocyclic compounds as BCL-2 inhibitors
US20230301989A1 (en) * 2020-08-21 2023-09-28 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
CN114073703B (en) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 Compositions and methods for treating nonalcoholic steatohepatitis
JP2023551056A (en) * 2020-11-25 2023-12-06 アセンテージ ファーマ(スーチョウ)カンパニー,リミティド Solid dispersion, pharmaceutical preparation, manufacturing method and application thereof
CN114681458B (en) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 Methods of treating multiple sclerosis
US20240166644A1 (en) * 2021-02-01 2024-05-23 Ascentage Pharma (Suzhou) Co., Ltd. Sulfonyl benzamide derivatives as bcl-2 inhibitors
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
WO2023011488A1 (en) 2021-08-02 2023-02-09 苏州亚盛药业有限公司 Pharmaceutical combination and use thereof
CN115260191B (en) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 Piperidine compound and preparation method and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
EP2061560A2 (en) 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
WO2008070663A2 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
UA108193C2 (en) * 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
EP3666758A1 (en) 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
AU2010204555B2 (en) 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012517241A (en) 2009-02-11 2012-08-02 アボット・ラボラトリーズ Methods and compositions for identifying, classifying and monitoring subjects with Bcl-2 family inhibitor resistant tumors and cancers
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2435432T6 (en) * 2009-05-26 2023-12-18 Abbvie Ireland Unlimited Co Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (en) * 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2811805A1 (en) * 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
KR101923364B1 (en) 2010-11-23 2018-11-30 애브비 인코포레이티드 Salts and crystalline forms of an apoptosis-inducing agent
DK2642999T3 (en) * 2010-11-23 2017-01-09 Abbvie Ireland Unlimited Co METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
CA3002482C (en) 2015-12-30 2021-06-08 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
EP3569601B1 (en) * 2016-08-05 2022-06-22 The Regents of The University of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Also Published As

Publication number Publication date
IL264059A (en) 2019-01-31
CN109311871B (en) 2020-02-28
US20190315739A1 (en) 2019-10-17
CN110483501B (en) 2022-07-01
DK3494115T3 (en) 2021-01-18
RU2744358C2 (en) 2021-03-05
HUE053414T2 (en) 2021-06-28
US10829488B2 (en) 2020-11-10
SG11201900135YA (en) 2019-02-27
EP3569601B1 (en) 2022-06-22
RS61821B1 (en) 2021-06-30
NZ750100A (en) 2021-01-29
RU2020134802A (en) 2022-04-25
CN109311871A (en) 2019-02-05
US20180354950A1 (en) 2018-12-13
CA3031419C (en) 2021-08-24
IL264059B (en) 2021-05-31
KR102376764B1 (en) 2022-03-18
JP2020007311A (en) 2020-01-16
EP3494115B1 (en) 2020-10-21
IL282099B (en) 2022-03-01
PT3494115T (en) 2021-01-15
ZA201908466B (en) 2020-05-27
MX2019001391A (en) 2019-06-06
EP3569601A2 (en) 2019-11-20
US10221174B2 (en) 2019-03-05
AU2017305508B2 (en) 2021-01-07
KR20210107170A (en) 2021-08-31
RU2722560C1 (en) 2020-06-01
RU2020114660A (en) 2020-06-19
AU2021202113A1 (en) 2021-05-06
EP3569601A3 (en) 2019-11-27
CN110483501A (en) 2019-11-22
SI3494115T1 (en) 2021-02-26
JP6651180B2 (en) 2020-02-19
AU2021202113B2 (en) 2022-08-18
PE20190711A1 (en) 2019-05-17
US20210002277A1 (en) 2021-01-07
WO2018027097A1 (en) 2018-02-08
EP4129999A1 (en) 2023-02-08
MX2020013014A (en) 2021-02-22
KR20190035710A (en) 2019-04-03
AU2017305508A1 (en) 2019-02-07
EP3494115A1 (en) 2019-06-12
ZA201900240B (en) 2020-05-27
US11718613B2 (en) 2023-08-08
HRP20202073T1 (en) 2021-02-19
SA519401020B1 (en) 2022-03-16
RU2020114660A3 (en) 2020-09-15
PH12019500231A1 (en) 2019-07-29
ES2849959T3 (en) 2021-08-24
CA3031419A1 (en) 2018-02-08
JP7205903B2 (en) 2023-01-17
IL282099A (en) 2021-05-31
CY1123859T1 (en) 2022-05-27
JP2019527705A (en) 2019-10-03
LT3494115T (en) 2021-01-25
KR102429704B1 (en) 2022-08-04
BR112019001666A2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
IL282099B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
IL272910A (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
IL265922A (en) Tyk2 inhibitors and uses thereof
IL266109A (en) Tyk2 inhibitors and uses thereof
SG11202009933WA (en) Bcl-2 INHIBITORS
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
DK3672976T3 (en) BCL-2 INHIBITORS
HK1253040A1 (en) Novel jak1 selective inhibitors and uses thereof
PT3532459T (en) Lsd1 inhibitors and medical uses thereof
HK1251174A1 (en) Benzamide and active compound compositions and methods of use
HK1252567A1 (en) Substituted benzamides and methods of use thereof
LT3621694T (en) Lrrc33 inhibitors and use thereof
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
DK3240821T3 (en) LOW DOSE GASHYDRATE INHIBITOR COMPOSITION AND ASSOCIATED PROCEDURE
IL247921A0 (en) Glutaminase inhibitor compounds, compositions comprising same and uses thereof
IL266861A (en) Benzamide and active compound compositions and methods of use
HK1255029A1 (en) Gelatinase inhibitors and use thereof
DK3712162T3 (en) SMAC-MIMETICS USED AS IAP INHIBITORS AND USES THEREOF
DK3551634T3 (en) SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND USE THEREOF AS PHOSPHODIESTERASE INHIBITORS
HUE047857T2 (en) Bis (sulfonamide) derivatives and their use as mpges inhibitors